The elimination of furazolidone and its open-chain cyano-derivative from adult swine

References

• Abraham R. T. Metabolic degradation of furazolidone: identification of convergent reductive pathways in rat liver and intestinal flora. University of Pittsburgh. 1981, Ph.D. dissertation
   Google Scholar
• Abraham R. T., Knapp J. E., Minnigh M. B., Wong L. K., Zemaitis M. A., Alvin J. D. Reductive metabolism of furazolidone by Escherichia coli and rat liver in vitro. Drug Metabolism and Disposition 1984; 12: 732–741
   PubMed Web of Science ®Google Scholar
• Brander G. C., Pugh D. M. Veterinary Applied Pharmacology and Therapeutics, 2nd edition. Baillière Tindall, London 1971
   Google Scholar
• Food and Drug Administration. Part V. New Animal Drugs. Furazolidone (NF-180). Federal Register 1976; 41: 19906–19921
   Google Scholar
• Kalim H. Zum Nachweis von Furazolidone in Körpergeweben und-flüssigkeiten von Kalb und Schwein mittels Hochdruckflüssigkeits-chromatographie. Dissertations- und Fotodruck Frank GmbH, München 1985, Ph.D. Dissertation, Tierärt-ztliche Fakultät der Universität München
   Google Scholar
• Klemencic J., Wang C. Y. Mutagenicity of Nitrofurans. Carcinogenesis: Nitrofurans, G. T. Bryan. Raven Press, New York 1978; 99–130
   Google Scholar
• Maron D. M., Ames B. N. Revised methods for the Salmonella mutagenicity test. Mutation Research 1983; 113: 173–215
   PubMed Web of Science ®Google Scholar
• McCalla D. R. Mutagenicity of nitrofuran derivatives: review. Environmental Mutagenesis 1983; 5: 745–765
   PubMedGoogle Scholar
• Nakabeppu H., Tatsumi K. Metabolism of furazolidone in eels. Chemical and Pharmaceutical Bulletin 1984; 32: 4193–4196
   PubMed Web of Science ®Google Scholar
• Olive P. L. Macromolecular, antineoplastic and radiosensitization effects of nitrofurans. Carcinogenesis: Nitrofurans, G. T. Bryan. Raven Press, New York 1978; 131–170
   Google Scholar
• Ravindranath V., Burka L. T., Boyd M. R. Reactive metabolites from the bioactivation of toxic methylfurans. Science 1984; 224: 884–886
   PubMed Web of Science ®Google Scholar
• Rossoff I. S. Handbook of Veterinary Drugs, a compendium for research and clinical use. Spring Publishing Company, New York 1974
   Google Scholar
• Rozenkranz H. S., Speck W. T. Activation of nitrofurantoin to a mutagen by rat liver nitroreductase. Biochemical Pharmacology 1976; 25: 1555–1556
   PubMed Web of Science ®Google Scholar
• Schmid A. Toxicologische Beurteilung von Nitrofuran-derivaten. Tierärtztliche Praxis 1985; 13: 471–477
   PubMedGoogle Scholar
• Short C. R., Maines M. D., Westfall B. A. Postnatal development of drug-metabolizing enzyme activity in liver and extrahepatic tissues of swine. Biologia Neonatorum 1972; 21: 54–68
   Google Scholar
• Swaminathan S., Lower G. Biotransformations and excretion of nitrofurans. Carcinogenesis: Nitrofurans, G. T. Bryan. Raven Press, New York 1978; 59–98
   Google Scholar
• Tatsumi K., Nakabeppu, Takahashi H. Y., Kitamura S. Metabolism in vivo of furazolidone: evidence for the formation of a open-chain carboxylic acid and α-ketoglutaric acid from the nitrofuran in rats. Archives of Biochemistry and Biophysics 1984; 234: 112–116
   PubMed Web of Science ®Google Scholar
• Tatsumi K., Ou T., Yamada H., Yoshimura H., Koga H., Horiuchi T. Isolation and identification of the metabolite of N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone (furazolidone). Journal of Pharmacobio-Dynamics 1978; 1: 256–261
   Google Scholar
• Tatsumi K., Yamada H., Yoshimura H., Kawazoe Y. Metabolism of furazolidone by milk xanthine oxidase and rat liver 9000 g supernatant: formation of an unique nitrofuran metabolite and an aminofuran derivative. Archives of Biochemistry and Biophysics 1981; 208: 167–174
   PubMed Web of Science ®Google Scholar
• Tennent D. M., Ray W. H. Metabolism of furazolidone in swine (35994). Proceedings of the Society for Experimental Biology and Medicine 1971; 138: 808–810
   PubMed Web of Science ®Google Scholar
• VanEsch G. J., Van Der Heijden C. A., Van Klingeren B., Voogd C. E. Samenvatting en beoordeling van onderzoekgegevens betreffende de schadelijke bijwerkingen van furazolidon en zijn metabolieten. Rijksinstituut voor de Volksgezondheid, Bilthoven 1983, rapportnummer 358301001
   Google Scholar
• Veale H. S., Harrington G. W. Determination of furazolidone in swine plasma using liquid chromatography. Journal of Chromatography 1982; 240: 230–234
   PubMed Web of Science ®Google Scholar
• Vroomen L. H. M., Berghmans M. C. J., Van Leeuwena P., Struijs T. D. B., De Van Der Vries P. H. U., Kuiper H. A. Kinetics of 14C-furazolidone in piglets upon oral administration during 10 days and its interaction with tissue macro-molecules. Food Additives and Contaminants 1986a; 3: 331–346
   Web of Science ®Google Scholar
• Vroomen L. H. M., Berghmans M. C. J., Van Der Struijs T. D. B. Determination of furazolidone in swine plasma, muscle, liver, kidney, fat and urine based on high-performance liquid chromatographic separation after solid-phase extraction of Extrelutr` 1. Journal of Chromatography 1986b; 362: 141–145
   PubMed Web of Science ®Google Scholar
• Vroomen L. H. M., Van Ommen B., Van Bladeren P. J. Quantitative studies of the metabolism of furazolidone by rat liver microsomes. Toxicology In-Vitro 1987; 1: 97–104
   PubMed Web of Science ®Google Scholar
• Winterlin W., Mourer Ch., Hall G., Kratzer F., Weaver G. L. H., Tribble L. F., Kim S. M. Furazolidone residues in chicken and swine tissues after feeding trials. Journal of Environmental Science and Health 1984; B19: 209–224
   Web of Science ®Google Scholar
• Yamamoto H., Yamaoka R., Kohanawa M. Residue of furazolidone in swine administered orally. Annual Reports of the National Veterinary Assay Laboratory 1978; 15: 57–61
   Google Scholar